Global Cancer Immunotherapies Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Market Overview

• 1.1 Cancer Immunotherapies Introduction
• 1.2 Market Analysis by Type
  • 1.2.1 Monoclonal Antibodies (MABs)
  • 1.2.2 Cancer Vaccines
  • 1.2.3 Immunomodulators
  • 1.2.4 Adoptive Cell transfer
  • 1.2.5 Checkpoint Inhibitors
• 1.3 Market Analysis by Applications
  • 1.3.1 Breast Cancer
  • 1.3.2 Leukemia
  • 1.3.3 Lymphoma
  • 1.3.4 Melanoma
  • 1.3.5 Colorectal Cancer
  • 1.3.6 Non-Small Cell Lung Cancer
• 1.4 Market Analysis by Regions
  • 1.4.1 North America (United States, Canada and Mexico)
    • 1.4.1.1 United States Market States and Outlook (2014-2024)
    • 1.4.1.2 Canada Market States and Outlook (2014-2024)
    • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
    • 1.4.2.1 Germany Market States and Outlook (2014-2024)
    • 1.4.2.2 France Market States and Outlook (2014-2024)
    • 1.4.2.3 UK Market States and Outlook (2014-2024)
    • 1.4.2.4 Russia Market States and Outlook (2014-2024)
    • 1.4.2.5 Italy Market States and Outlook (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
    • 1.4.3.1 China Market States and Outlook (2014-2024)
    • 1.4.3.2 Japan Market States and Outlook (2014-2024)
    • 1.4.3.3 Korea Market States and Outlook (2014-2024)
    • 1.4.3.4 India Market States and Outlook (2014-2024)
    • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
  • 1.4.4 South America, Middle East and Africa
    • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
    • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
    • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
    • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
    • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
• 1.5 Market Dynamics
  • 1.5.1 Market Opportunities
  • 1.5.2 Market Risk
  • 1.5.3 Market Driving Force

2 Manufacturers Profiles

• 2.1 Amgen
  • 2.1.1 Business Overview
  • 2.1.2 Cancer Immunotherapies Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Amgen Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 AstraZeneca
  • 2.2.1 Business Overview
  • 2.2.2 Cancer Immunotherapies Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 AstraZeneca Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Roche
  • 2.3.1 Business Overview
  • 2.3.2 Cancer Immunotherapies Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Roche Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Bristol-Myers Squibb
  • 2.4.1 Business Overview
  • 2.4.2 Cancer Immunotherapies Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Bayer
  • 2.5.1 Business Overview
  • 2.5.2 Cancer Immunotherapies Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Bayer Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Merck
  • 2.6.1 Business Overview
  • 2.6.2 Cancer Immunotherapies Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Merck Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 ARMO BioSciences (Eli Lilly)
  • 2.7.1 Business Overview
  • 2.7.2 Cancer Immunotherapies Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Novartis
  • 2.8.1 Business Overview
  • 2.8.2 Cancer Immunotherapies Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Novartis Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Pfizer
  • 2.9.1 Business Overview
  • 2.9.2 Cancer Immunotherapies Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Pfizer Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Johnson & Johnson
  • 2.10.1 Business Overview
  • 2.10.2 Cancer Immunotherapies Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 AbbVie
  • 2.11.1 Business Overview
  • 2.11.2 Cancer Immunotherapies Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 AbbVie Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Gilead Sciences
  • 2.12.1 Business Overview
  • 2.12.2 Cancer Immunotherapies Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Gilead Sciences Cancer Immunotherapies Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

3 Global Cancer Immunotherapies Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

• 3.1 Global Cancer Immunotherapies Sales and Market Share by Manufacturer (2017-2018)
• 3.2 Global Cancer Immunotherapies Revenue and Market Share by Manufacturer (2017-2018)
• 3.3 Market Concentration Rate
  • 3.3.1 Top 3 Cancer Immunotherapies Manufacturer Market Share in 2018
  • 3.3.2 Top 6 Cancer Immunotherapies Manufacturer Market Share in 2018
• 3.4 Market Competition Trend

4 Global Cancer Immunotherapies Market Analysis by Regions

• 4.1 Global Cancer Immunotherapies Sales, Revenue and Market Share by Regions
  • 4.1.1 Global Cancer Immunotherapies Sales and Market Share by Regions (2014-2019)
  • 4.1.2 Global Cancer Immunotherapies Revenue and Market Share by Regions (2014-2019)
• 4.2 North America Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 4.3 Europe Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 4.5 South America Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Cancer Immunotherapies Sales and Growth Rate (2014-2019)

5 North America Cancer Immunotherapies by Country

• 5.1 North America Cancer Immunotherapies Sales, Revenue and Market Share by Country
  • 5.1.1 North America Cancer Immunotherapies Sales and Market Share by Country (2014-2019)
  • 5.1.2 North America Cancer Immunotherapies Revenue and Market Share by Country (2014-2019)
• 5.2 United States Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 5.3 Canada Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 5.4 Mexico Cancer Immunotherapies Sales and Growth Rate (2014-2019)

6 Europe Cancer Immunotherapies by Country

• 6.1 Europe Cancer Immunotherapies Sales, Revenue and Market Share by Country
  • 6.1.1 Europe Cancer Immunotherapies Sales and Market Share by Country (2014-2019)
  • 6.1.2 Europe Cancer Immunotherapies Revenue and Market Share by Country (2014-2019)
• 6.2 Germany Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 6.3 UK Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 6.4 France Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 6.5 Russia Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 6.6 Italy Cancer Immunotherapies Sales and Growth Rate (2014-2019)

7 Asia-Pacific Cancer Immunotherapies by Country

• 7.1 Asia-Pacific Cancer Immunotherapies Sales, Revenue and Market Share by Country
  • 7.1.1 Asia-Pacific Cancer Immunotherapies Sales and Market Share by Country (2014-2019)
  • 7.1.2 Asia-Pacific Cancer Immunotherapies Revenue and Market Share by Country (2014-2019)
• 7.2 China Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 7.3 Japan Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 7.4 Korea Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 7.5 India Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 7.6 Southeast Asia Cancer Immunotherapies Sales and Growth Rate (2014-2019)

8 South America Cancer Immunotherapies by Country

• 8.1 South America Cancer Immunotherapies Sales, Revenue and Market Share by Country
  • 8.1.1 South America Cancer Immunotherapies Sales and Market Share by Country (2014-2019)
  • 8.1.2 South America Cancer Immunotherapies Revenue and Market Share by Country (2014-2019)
• 8.2 Brazil Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 8.3 Argentina Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 8.4 Colombia Cancer Immunotherapies Sales and Growth Rate (2014-2019)

9 Middle East and Africa Cancer Immunotherapies by Countries

• 9.1 Middle East and Africa Cancer Immunotherapies Sales, Revenue and Market Share by Country
  • 9.1.1 Middle East and Africa Cancer Immunotherapies Sales and Market Share by Country (2014-2019)
  • 9.1.2 Middle East and Africa Cancer Immunotherapies Revenue and Market Share by Country (2014-2019)
• 9.2 Saudi Arabia Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 9.3 Turkey Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 9.4 Egypt Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 9.5 Nigeria Cancer Immunotherapies Sales and Growth Rate (2014-2019)
• 9.6 South Africa Cancer Immunotherapies Sales and Growth Rate (2014-2019)

10 Global Cancer Immunotherapies Market Segment by Type

• 10.1 Global Cancer Immunotherapies Sales, Revenue and Market Share by Type (2014-2019)
  • 10.1.1 Global Cancer Immunotherapies Sales and Market Share by Type (2014-2019)
  • 10.1.2 Global Cancer Immunotherapies Revenue and Market Share by Type (2014-2019)
• 10.2 Monoclonal Antibodies (MABs) Sales Growth and Price
  • 10.2.1 Global Monoclonal Antibodies (MABs) Sales Growth (2014-2019)
  • 10.2.2 Global Monoclonal Antibodies (MABs) Price (2014-2019)
• 10.3 Cancer Vaccines Sales Growth and Price
  • 10.3.1 Global Cancer Vaccines Sales Growth (2014-2019)
  • 10.3.2 Global Cancer Vaccines Price (2014-2019)
• 10.4 Immunomodulators Sales Growth and Price
  • 10.4.1 Global Immunomodulators Sales Growth (2014-2019)
  • 10.4.2 Global Immunomodulators Price (2014-2019)
• 10.5 Adoptive Cell transfer Sales Growth and Price
  • 10.5.1 Global Adoptive Cell transfer Sales Growth (2014-2019)
  • 10.5.2 Global Adoptive Cell transfer Price (2014-2019)
• 10.6 Checkpoint Inhibitors Sales Growth and Price
  • 10.6.1 Global Checkpoint Inhibitors Sales Growth (2014-2019)
  • 10.6.2 Global Checkpoint Inhibitors Price (2014-2019)

11 Global Cancer Immunotherapies Market Segment by Application

• 11.1 Global Cancer Immunotherapies Sales Market Share by Application (2014-2019)
• 11.2 Breast Cancer Sales Growth (2014-2019)
• 11.3 Leukemia Sales Growth (2014-2019)
• 11.4 Lymphoma Sales Growth (2014-2019)
• 11.5 Melanoma Sales Growth (2014-2019)
• 11.6 Colorectal Cancer Sales Growth (2014-2019)
• 11.7 Non-Small Cell Lung Cancer Sales Growth (2014-2019)

12 Cancer Immunotherapies Market Forecast (2019-2024)

• 12.1 Global Cancer Immunotherapies Sales, Revenue and Growth Rate (2019-2024)
• 12.2 Cancer Immunotherapies Market Forecast by Regions (2019-2024)
  • 12.2.1 North America Cancer Immunotherapies Market Forecast (2019-2024)
  • 12.2.2 Europe Cancer Immunotherapies Market Forecast (2019-2024)
  • 12.2.3 Asia-Pacific Cancer Immunotherapies Market Forecast (2019-2024)
  • 12.2.4 South America Cancer Immunotherapies Market Forecast (2019-2024)
  • 12.2.5 Middle East and Africa Cancer Immunotherapies Market Forecast (2019-2024)
• 12.3 Cancer Immunotherapies Market Forecast by Type (2019-2024)
  • 12.3.1 Global Cancer Immunotherapies Sales Forecast by Type (2019-2024)
  • 12.3.2 Global Cancer Immunotherapies Market Share Forecast by Type (2019-2024)
• 12.4 Cancer Immunotherapies Market Forecast by Application (2019-2024)
  • 12.4.1 Global Cancer Immunotherapies Sales Forecast by Application (2019-2024)
  • 12.4.2 Global Cancer Immunotherapies Market Share Forecast by Application (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

• 13.1 Sales Channel
  • 13.1.1 Direct Marketing
  • 13.1.2 Indirect Marketing
  • 13.1.3 Marketing Channel Future Trend
• 13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

• 15.1 Methodology